Mankind Pharma Limited (MANKIND) Operating Income 2023–2026

Name: Mankind Pharma Limited (MANKIND) operating income history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Mankind Pharma Limited annual operating income for fiscal 2026 was ₹28.4 billion, an increase of 12.7% from ₹25.2 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

MANKIND Annual Operating Income

Operating Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Operating Income (EBIT)	₹28.4B	₹25.2B	₹22.4B	₹16.4B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MANKIND Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Operating Income (EBIT)	₹8.3B	₹7.1B	₹7.0B	₹6.3B	₹4.5B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

LAURUSLABS Operating Income — Laurus Labs Limited
AUROPHARMA Operating Income — Aurobindo Pharma Limited
DRREDDY Operating Income — Dr. Reddy's Laboratories Limited
LUPIN Operating Income — Lupin Limited
4506 Operating Income — Sumitomo Pharma Co., Ltd.
GLENMARK Operating Income — Glenmark Pharmaceuticals Limited

More MANKIND metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All MANKIND financial statements → Interactive MANKIND charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.